Announcement
Super Grannies and Market Update – June 30 Webinar Cancelled

Horizon Therapeutics Is Inexpensive; 2 Drugs Show Promise

-HZNP’s Tepezza drug for thyroid eye disease showed stronger than expected 1Q20 growth

-Even after a post-1Q20 report jump, HZNP shares still reasonable value vs growth potential

-Both Tepezza an Krystexxa medicines show promise; stock could rise up to 30%

If the stock market recovery is for real, and we think it is, some investors might move away from more defensive equities such as healthcare shares. That’s understandable, but all portfolios can benefit from balance and diversity, so don’t ...

Finish reading this report for free

Enter your email and we’ll send the paywall-free report directly to your inbox

In addition to your unlocked report, you will receive our weekly market newsletter FSI Snapshot, as well as occasional updates and offers from FS Insight. You can unsubscribe at any time. For more information, see our privacy policy.

Get unlimited access to Tom Lee’s Fundstrat research Subscribe
Already a member? Log in
Disclosures (show)

Get invaluable analysis of the market and stocks. Cancel at any time. Start Free Trial

Articles Read 2/2

🎁 Unlock 1 extra article by joining our Community!

You are reading the last free article for this month.

By continuing, you agree to the Terms of Service and Privacy Policy.

Already have an account? Sign In

Events

Featured Research

Washed Out Stocks

Trending tickers in our research